Deutsche Bank has retained GlaxoSmithKline PLC (LON:GSK) to Hold in a statement released on 4/12/2017.
Previously on 4/03/2017, Exane BNP Paribas reported on GlaxoSmithKline PLC (LON:GSK) maintained the target price at 1,520.00GBX that suggested a downside of -0.08%.
Recent Performance Chart
With a total market value of 0 GBX, GlaxoSmithKline PLC has price-earnings ratio of 88.48 with a one year low of 1,363.00GBX and a 52 week high of 1,745.56GBX .
Also covering GlaxoSmithKline PLC's stock price target, a total of 24 brokers have issued a research note on the company. The average stock price target is 1,577.33GBX with three analysts rating the company a strong buy, six brokerages rating the company a buy, seventeen brokerages rating the company a hold, two equity analysts rating the company a underperform, and lastly zero brokers rating the stock a sell.
General Information About GlaxoSmithKline PLC (LON:GSK)
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
The post GlaxoSmithKline PLC (LON:GSK) has been retained to Hold in a statement by Deutsche Bank earlier today. appeared first on Octafinance.